IRIS Accounts Production v25.3.0.601 15499226 director 18.2.24 28.2.25 28.2.25 6.11.2025 0 false true false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 15499226 2024-02-17 15499226 2025-02-28 15499226 2024-02-18 2025-02-28 15499226 2024-02-17 15499226 ns15:EnglandWales 2024-02-18 2025-02-28 15499226 ns14:PoundSterling 2024-02-18 2025-02-28 15499226 ns10:Director1 2024-02-18 2025-02-28 15499226 ns10:PrivateLimitedCompanyLtd 2024-02-18 2025-02-28 15499226 ns10:SmallEntities 2024-02-18 2025-02-28 15499226 ns10:Audited 2024-02-18 2025-02-28 15499226 ns10:SmallCompaniesRegimeForDirectorsReport 2024-02-18 2025-02-28 15499226 ns10:SmallCompaniesRegimeForAccounts 2024-02-18 2025-02-28 15499226 ns10:FullAccounts 2024-02-18 2025-02-28 15499226 ns10:RegisteredOffice 2024-02-18 2025-02-28 15499226 ns5:CurrentFinancialInstruments 2025-02-28 15499226 ns5:Non-currentFinancialInstruments 2025-02-28 15499226 ns5:ShareCapital 2025-02-28 15499226 ns5:RetainedEarningsAccumulatedLosses 2025-02-28 15499226 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-02-28 15499226 ns5:MoreThanFiveYears ns5:Non-currentFinancialInstruments 2025-02-28

REGISTERED NUMBER: 15499226 (England and Wales)

| FINANCIAL STATEMENTS |

| FOR THE PERIOD |

| 18 FEBRUARY 2024 TO 28 FEBRUARY 2025 |

| FOR |

| MIDLAND PHARMACEUTICALS LTD |

MIDLAND PHARMACEUTICALS LTD (REGISTERED NUMBER: 15499226) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE PERIOD 18 FEBRUARY 2024 TO 28 FEBRUARY 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| MIDLAND PHARMACEUTICALS LTD |

COMPANY INFORMATION

FOR THE PERIOD 18 FEBRUARY 2024 TO 28 FEBRUARY 2025

| DIRECTOR: | P Suzdak

| REGISTERED OFFICE: | C/o Philip Lee

| 30th Floor Leadenhall Building

| 122 Leadenhall St

| London

| EC3V 4AB

| REGISTERED NUMBER: | 15499226 (England and Wales)

| AUDITORS: | Armstrongs Accountancy Ltd

| Chartered Accountants and Statutory Auditor

| 1 & 2 Mercia Village

| Torwood Close

| Westwood Business Park

| Coventry

| West Midlands

| CV4 8HX

MIDLAND PHARMACEUTICALS LTD (REGISTERED NUMBER: 15499226) |

BALANCE SHEET

28 FEBRUARY 2025

| Notes | £ |

| CURRENT ASSETS

| Debtors | 4 | 5,100 |  |

| Cash at bank | 99,852 |  |

104,952 |  |

| CREDITORS

| Amounts falling due within one year | 5 | 7,439 |  |

| NET CURRENT ASSETS | 97,513 |  |

| TOTAL ASSETS LESS CURRENT LIABILITIES | 97,513 |  |

| CREDITORS

| Amounts falling due after more than one year | 6 | 130,726 |  |

| NET LIABILITIES | (33,213 | ) |

| CAPITAL AND RESERVES

| Called up share capital | 8 |  |

| Retained earnings | (33,221 | ) |

(33,213 | ) |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 6 November 2025 and were signed by:

P Suzdak - Director

MIDLAND PHARMACEUTICALS LTD (REGISTERED NUMBER: 15499226) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD 18 FEBRUARY 2024 TO 28 FEBRUARY 2025

1. | STATUTORY INFORMATION

| Midland Pharmaceuticals Ltd is a private limited company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£), rounded to the nearest pound.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Going concern

| The company is currently in the product development phase and intends to raise funds through series A financing by the end of 2025. The director is confident that the company has adequate support and funds to sustain its product development activities. Therefore the financial statements have been prepared on going concern basis due to the company's ability to continue its operation.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the period was NIL.

4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

£ |

| Amounts owed by group undertakings | 4,013 |  |

| Directors' current accounts | 7 |  |

| Prepayments and accrued income | 1,080 |  |

5,100 |  |

5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

£ |

| Trade creditors | 3,659 |  |

| Accrued expenses | 3,780 |  |

7,439 |  |

6. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

£ |

| Other loans - 2-5 years | 130,726 |  |

MIDLAND PHARMACEUTICALS LTD (REGISTERED NUMBER: 15499226) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE PERIOD 18 FEBRUARY 2024 TO 28 FEBRUARY 2025

7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Muhammed Shabbir (Senior Statutory Auditor)

| for and on behalf of Armstrongs Accountancy Ltd

8. | ULTIMATE CONTROLLING PARTY

| The ultimate controlling party is NLC Ventures Netherlands B.V..

| The registered address of the parent is 25 Paasheuvelweg, Amsterdam, Netherlands 1105 BP.